The challenge of clinical end points in sickle cell disease
Document Type
Article
Publication Date
12-14-2023
Publication Title
Blood
Volume
142
Issue
24
Funding Sponsor
National Institutes of Health
Abstract
As most patients with sickle cell disease (SCD) do not have access to curative therapies, the availability of drug therapies that can modify disease severity remains highly desirable. Despite an increased understanding of the pathophysiology of SCD, only 4 drugs are approved by the US Food and Drugs Administration. Most drug trials in SCD have involved the use of acute pain episodes as the primary clinical end point. These studies have typically been to prevent or shorten the duration of such episodes. To date, no drug has received regulatory approval for shortening the duration of acute vaso-occlusive complications, likely highlighting the complex pathophysiology of acute pain episodes. Trials to prevent acute pain episodes have largely evaluated those episodes requiring health care use as a surrogate end point. However, with differences in culture and health care practices among countries, health care use may not reliably predict clinically important effects on acute pain episodes. This article discusses issues related to the use of health care use as the primary end point for prevention trials of acute pain episodes and highlights the importance of evaluating patient-reported outcomes as well as other SCD-related complications as outcome measures.
Recommended Citation
Ataga, Kenneth I., "The challenge of clinical end points in sickle cell disease" (2023). Faculty Publications. 10. 10.1182/blood.2023021220
https://dc.uthsc.edu/fac_pubs/10